Trials / Unknown
UnknownNCT04445467
An Adaptive Clinical Trial of Antivirals for COVID-19 Infection
An Adaptive Randomised Placebo Controlled Phase II Trial of Antivirals for COVID-19 Infection
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 190 (actual)
- Sponsor
- Bayside Health · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomised placebo controlled phase II trial to examine the efficacy of antivirals to treat COVID-19 infection compared to placebo for virological cure and improved clinical outcomes. Individuals will be randomised to the candidate antiviral which in the first instance is Favipiravir or matched placebo and randomisation will be stratified according to whether the participant requires hospitalisation or not. This treatment will be given in addition to the usual standard of care in the participating hospital.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Favipiravir | Favipiravir |
Timeline
- Start date
- 2020-07-30
- Primary completion
- 2021-11-01
- Completion
- 2021-12-01
- First posted
- 2020-06-24
- Last updated
- 2021-10-07
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT04445467. Inclusion in this directory is not an endorsement.